Cargando…

Identification of Immunogenic MHC Class II Human HER3 Peptides that Mediate Anti-HER3 CD4(+) Th1 Responses and Potential Use as a Cancer Vaccine

The HER3/ERBB3 receptor is an oncogenic receptor tyrosine kinase that forms heterodimers with EGFR family members and is overexpressed in numerous cancers. HER3 overexpression associates with reduced survival and acquired resistance to targeted therapies, making it a potential therapeutic target in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Basu, Amrita, Albert, Gabriella K., Awshah, Sabrina, Datta, Jashodeep, Kodumudi, Krithika N., Gallen, Corey, Beyer, Amber, Smalley, Keiran S.M., Rodriguez, Paulo C., Duckett, Derek R., Forsyth, Peter A., Soyano, Aixa, Koski, Gary K., Lima Barros Costa, Ricardo, Han, Heather, Soliman, Hatem, Lee, Marie Catherine, Kalinski, Pawel, Czerniecki, Brian J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Association for Cancer Research 2022
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9414303/ https://www.ncbi.nlm.nih.gov/pubmed/34785506 http://dx.doi.org/10.1158/2326-6066.CIR-21-0454

Ejemplares similares

A Murine Ommaya Xenograft Model to Study Direct-Targeted Therapy of Leptomeningeal Disease
por: Law, Vincent, et al.
Publicado: (2021)

Intratumoral delivery of dendritic cells plus anti-HER2 therapy triggers both robust systemic antitumor immunity and complete regression in HER2 mammary carcinoma
por: Ramamoorthi, Ganesan, et al.
Publicado: (2022)

Oncodriver inhibition and CD4(+) Th1 cytokines cooperate through Stat1 activation to induce tumor senescence and apoptosis in HER2+ and triple negative breast cancer: implications for combining immune and targeted therapies
por: Rosemblit, Cinthia, et al.
Publicado: (2018)

Murine Dendritic Cells Grown in Serum-Free Culture Show Potent Therapeutic Activity when Loaded with Novel Th Epitopes in an Orthotopic Model of HER2(pos) Breast Cancer
por: Showalter, Loral E., et al.
Publicado: (2021)

BSCI-01 INTRATHECAL DELIVERY OF DENDRITIC CELL VACCINE ERADICATES TUMOR GROWTH AND PROTECTS AGAINST LEPTOMENINGEAL DISEASE (LMD) RE-INOCULATION IN IMMUNOCOMPETENT HER2+ AND TRIPLE NEGATIVE BREAST CANCER (TNBC) LMD XENOGRAFT MODELS
por: Law, Vincent, et al.
Publicado: (2022)

Sequential Anti-PD1 Therapy Following Dendritic Cell Vaccination Improves Survival in a HER2 Mammary Carcinoma Model and Identifies a Critical Role for CD4 T Cells in Mediating the Response
por: Kodumudi, Krithika N., et al.
Publicado: (2019)

Differentiation and Regulation of T(H) Cells: A Balancing Act for Cancer Immunotherapy
por: Basu, Amrita, et al.
Publicado: (2021)

Th1 cytokine interferon gamma improves response in HER2 breast cancer by modulating the ubiquitin proteasomal pathway
por: Jia, Yongsheng, et al.
Publicado: (2021)

A brief report of toxicity end points of HER2 vaccines for the treatment of patients with HER2(+) breast cancer
por: Costa, Ricardo, et al.
Publicado: (2019)

HER3 Expression Is a Marker of Tumor Progression in Premalignant Lesions of the Gastroesophageal Junction
por: Ecker, Brett L., et al.
Publicado: (2016)

Th1 cytokines sensitize HER-expressing breast cancer cells to lapatinib
por: Showalter, Loral E., et al.
Publicado: (2019)

T-helper 1-type cytokines induce apoptosis and loss of HER-family oncodriver expression in murine and human breast cancer cells
por: Namjoshi, Prachi, et al.
Publicado: (2019)

Factors improving overall survival in breast cancer patients with leptomeningeal disease (LMD): A single institutional retrospective review
por: Wallace, Gerald, et al.
Publicado: (2023)

Clinical development of immunotherapies for HER2(+) breast cancer: a review of HER2-directed monoclonal antibodies and beyond
por: Costa, Ricardo L. B., et al.
Publicado: (2020)

Anti-HER2 CD4(+) T-helper type 1 response is a novel immune correlate to pathologic response following neoadjuvant therapy in HER2-positive breast cancer
por: Datta, Jashodeep, et al.
Publicado: (2015)

HER kinase inhibition in patients with HER2- and HER3-mutant cancers
por: Hyman, David M., et al.
Publicado: (2018)

Cytogenetic analysis of HER1/EGFR, HER2, HER3 and HER4 in 278 breast cancer patients
por: Sassen, Andrea, et al.
Publicado: (2008)

Trastuzumab Emtansine (T-DM1) and stereotactic radiation in the management of HER2+ breast cancer brain metastases
por: Mills, Matthew N., et al.
Publicado: (2021)

The role of HER2 and HER3 in HER2-amplified cancers beyond breast cancers
por: Majumder, Avisek, et al.
Publicado: (2021)

Novel strategy to identify MHC class II-promiscuous CD4+ peptides from tumor antigens for utilization in vaccination
por: Datta, Jashodeep, et al.
Publicado: (2014)

HER-3 expression in HER-2-amplified breast carcinoma
por: Czopek, Jacek, et al.
Publicado: (2013)

Sunitinib Combined with Th1 Cytokines Potentiates Apoptosis in Human Breast Cancer Cells and Suppresses Tumor Growth in a Murine Model of HER-2(pos) Breast Cancer
por: Ghimirey, Nirmala, et al.
Publicado: (2021)

Why do women with melanoma do better than men?
por: Smalley, Keiran SM
Publicado: (2018)

Model-Based Analysis of HER Activation in Cells Co-Expressing EGFR, HER2 and HER3
por: Shankaran, Harish, et al.
Publicado: (2013)

Novel agents that downregulate EGFR, HER2, and HER3 in parallel
por: Ferreira, Renan Barroso, et al.
Publicado: (2015)

Overexpression of HER2/HER3 and clinical feature of ovarian cancer
por: Chung, Ye Won, et al.
Publicado: (2019)

Mutant HER2 needs mutant HER3 to be an effective oncogene
por: Trenker, Raphael, et al.
Publicado: (2021)

The relation between survival and expression of HER1 and HER2 depends on the expression of HER3 and HER4: a study in bladder cancer patients
por: Memon, A A, et al.
Publicado: (2006)

Novel association of DJ-1 with HER3 potentiates HER3 activation and signaling in cancer
por: Zhang, Shu, et al.
Publicado: (2016)

Intercepting Premalignant, Preinvasive Breast Lesions Through Vaccination
por: Zachariah, Nadia Nocera, et al.
Publicado: (2021)

Targeting HER proteins in cancer therapy and the role of the non-target HER3
por: Hsieh, A C, et al.
Publicado: (2007)

Prognostic significance of HER3 and HER4 protein expression in colorectal adenocarcinomas
por: Kountourakis, Panteleimon, et al.
Publicado: (2006)

HER-2 and HER-3 expression in liver metastases of patients with colorectal cancer
por: Styczen, Hanna, et al.
Publicado: (2015)

Single-molecule functional anatomy of endogenous HER2-HER3 heterodimers
por: Choi, Byoungsan, et al.
Publicado: (2020)

HER3, p95HER2, and HER2 protein expression levels define multiple subtypes of HER2-positive metastatic breast cancer
por: Lipton, Allan, et al.
Publicado: (2013)

Inhibitor-induced HER2-HER3 heterodimerisation promotes proliferation through a novel dimer interface
por: Claus, Jeroen, et al.
Publicado: (2018)

Patritumab deruxtecan (HER3-DXd), a novel HER3 directed antibody drug conjugate, exhibits in vitro activity against breast cancer cells expressing HER3 mutations with and without HER2 overexpression
por: Koyama, Kumiko, et al.
Publicado: (2022)

Correlation of HER2, p95HER2 and HER3 Expression and Treatment Outcome of Lapatinib plus Capecitabine in her2-Positive Metastatic Breast Cancer
por: Han, Sae-Won, et al.
Publicado: (2012)

Targetable HER3 functions driving tumorigenic signaling in HER2-amplified cancers
por: Campbell, Marcia R., et al.
Publicado: (2022)

Extensive conformational and physical plasticity protects HER2-HER3 tumorigenic signaling
por: Campbell, Marcia R., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_vh5o6fb8gi710peseu9bpgmdjq